<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "9: clinical trial", fill: "#004b49"},
{source: "9: clinical trial", target: "9: recruitment", fill: "#004b49"},
{source: "9: recruitment", target: "9: patients based on ethnicity", fill: "#004b49"},
{source: "9: patients based on ethnicity", target: "9: haplotype status recruitment rates may", fill: "#004b49"},
{source: "9: haplotype status recruitment rates may", target: "9: thus delaying", fill: "#004b49"},
{source: "9: clinical trial", target: "10: Phase III ", fill: "#edc9af"},
{source: "10: Phase III ", target: "10: clinical trial", fill: "#edc9af"},
{source: "10: clinical trial", target: "10: African American ", fill: "#edc9af"},
{source: "10: African American ", target: "10: hospitalization", fill: "#edc9af"},
{source: "10: hospitalization", target: "10: admission", fill: "#edc9af"},
{source: "10: admission", target: "10: infarction", fill: "#edc9af"},
{source: "10: infarction", target: "10: cardiovascular", fill: "#edc9af"},
{source: "10: cardiovascular", target: "10: placebo on top", fill: "#edc9af"},
{source: "10: placebo on top", target: "10: concomitantly administered", fill: "#edc9af"},
{source: "10: Phase III ", target: "25: Expiration ", fill: "#d6cadd"},
{source: "25: Expiration ", target: "25: patents prior", fill: "#d6cadd"},
{source: "25: patents prior", target: "25: regulatory", fill: "#d6cadd"},
{source: "25: regulatory", target: "25: approval may affect", fill: "#d6cadd"},
{source: "25: approval may affect", target: "25: such possible", fill: "#d6cadd"},
{source: "25: Expiration ", target: "29: technology", fill: "#c08081"},
{source: "29: technology", target: "29: research capabilities", fill: "#c08081"},
{source: "29: research capabilities", target: "29: variations", fill: "#c08081"},
{source: "29: variations", target: "29: certain diseases", fill: "#c08081"},
{source: "29: certain diseases", target: "29: target proteins", fill: "#c08081"},
{source: "29: technology", target: "30: certain diseases", fill: "#4f7942"},
{source: "30: certain diseases", target: "30: drugs based on", fill: "#4f7942"},
{source: "30: drugs based on", target: "30: discoveries", fill: "#4f7942"},
{source: "30: certain diseases", target: "32: specific genes", fill: "#b57edc"},
{source: "32: specific genes", target: "32: partly responsible", fill: "#b57edc"},
{source: "32: partly responsible", target: "32: therapeutic", fill: "#b57edc"},
{source: "32: therapeutic", target: "32: diagnostic products", fill: "#b57edc"},
{source: "32: diagnostic products", target: "32: prevent treat", fill: "#b57edc"},
{source: "32: prevent treat", target: "32: particular disease", fill: "#b57edc"},
{source: "32: specific genes", target: "33: pharmaceutical", fill: "#8fbc8f"},
{source: "33: pharmaceutical", target: "33: diagnostic products", fill: "#8fbc8f"},
{source: "33: diagnostic products", target: "33: collaborators", fill: "#8fbc8f"},
{source: "33: collaborators", target: "33: revenues unless", fill: "#8fbc8f"},
{source: "33: revenues unless", target: "33: effective", fill: "#8fbc8f"},
{source: "33: effective", target: "33: successfully compete with", fill: "#8fbc8f"},
{source: "33: successfully compete with", target: "33: technologies", fill: "#8fbc8f"},
{source: "33: technologies", target: "33: proprietary rights", fill: "#8fbc8f"},
{source: "33: proprietary rights", target: "33: manufactured", fill: "#8fbc8f"},
{source: "33: manufactured", target: "33: sufficient quantities at", fill: "#8fbc8f"},
{source: "33: sufficient quantities at", target: "33: reasonable costs", fill: "#8fbc8f"},
{source: "33: reasonable costs", target: "33: regulatory approvals", fill: "#8fbc8f"},
{source: "33: regulatory approvals", target: "33: market them successfully", fill: "#8fbc8f"},
{source: "33: pharmaceutical", target: "35: significant revenue from", fill: "#00416a"},
{source: "35: significant revenue from", target: "35: development", fill: "#00416a"},
{source: "35: development", target: "35: therapeutic", fill: "#00416a"},
{source: "35: therapeutic", target: "35: diagnostic products", fill: "#00416a"},
{source: "35: significant revenue from", target: "73: successfully codevelop", fill: "#ff6700"},
{source: "73: successfully codevelop", target: "73: diagnostic", fill: "#ff6700"},
{source: "73: diagnostic", target: "73: partnerships", fill: "#ff6700"},
{source: "73: partnerships", target: "73: with manufacturing", fill: "#ff6700"},
{source: "73: with manufacturing", target: "73: marketing partners", fill: "#ff6700"},
{source: "73: successfully codevelop", target: "123: protect confidential data adequately", fill: "#556b2f"},
{source: "123: protect confidential data adequately", target: "123: could incur", fill: "#556b2f"},
{source: "123: could incur", target: "123: liability", fill: "#556b2f"},
{source: "123: protect confidential data adequately", target: "START_HERE", fill: "#556b2f"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preregistration_(science)">Preregistration (science)</a></td>
      <td>Preregistration is the practice of registering the hypotheses, methods, and/or analyses of a scientific study before it is conducted. This can include analyzing primary data or secondary data.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phase_III_offensive">Phase III offensive</a></td>
      <td>Phase III of the Tet offensive of 1968 (also known as the August offensive or Third offensive) was launched by the People's Army of Vietnam (PAVN) and Viet Cong (VC) from 17 August to 27 September 1968. The offensive was divided into two waves of attacks from 17 to 31 August 1968 and from 11 to 27 September of that same year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Covaxin">Covaxin</a></td>
      <td>Kurt Donald Cobain (February 20, 1967 – c. April 5, 1994) was an American singer, songwriter and artist.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bhadla_Solar_Park">Bhadla Solar Park</a></td>
      <td>Bhadla Solar Park is the largest solar park in the world as of 2021, and is spread over a total area of 5,700 hectares (14,000 acres) in Bhadla, Phalodi tehsil, Jodhpur district, Rajasthan, India.The park has a total capacity of 2245 MW. The park had witnessed the lowest bid for solar power in India as of December 2020 at ₹2.44 (3.2¢ US) per kilowatt-hour. In September 2018, Acme Solar announced that it had commissioned India's cheapest solar power: 200 MW at Bhadla.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Discovery_Channel">Discovery Channel</a></td>
      <td>Discovery Channel (known as The Discovery Channel from 1985 to 1995, and often referred to as simply Discovery) is an American cable channel owned by Warner Bros. Discovery, a publicly traded company run by CEO David Zaslav.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutics">Pharmaceutics</a></td>
      <td>Pharmaceutics is the discipline of pharmacy that deals with the process of turning a new chemical entity (NCE) or old drugs into a medication to be used safely and effectively by patients.  It is also called the science of dosage form design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy">Pharmacy</a></td>
      <td>Pharmacy is the clinical health science that links medical science with chemistry and it is charged with the discovery, production, disposal, safe and effective use, and control of medications and drugs. The practice of pharmacy requires excellent knowledge of drugs, their mechanism of action, side effects, interactions, mobility and toxicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Teva_Pharmaceuticals">Teva Pharmaceuticals</a></td>
      <td>Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_code">Pharmaceutical code</a></td>
      <td>Pharmaceutical codes are used in medical classification to uniquely identify medication. They may uniquely identify an active ingredient, drug system (including inactive ingredients and time-release agents) in general, or a specific pharmaceutical product from a specific manufacturer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sun_Pharma">Sun Pharma</a></td>
      <td>Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)  in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Janssen_Pharmaceuticals">Janssen Pharmaceuticals</a></td>
      <td>Janssen Pharmaceuticals is a pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson &amp; Johnson. It was founded in 1953 by Paul Janssen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limited_liability_partnership">Limited liability partnership</a></td>
      <td>A limited liability partnership (LLP) is a partnership in which some or all partners (depending on the jurisdiction) have limited liabilities. It therefore can exhibit elements of partnerships and corporations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>These statements relate to <font color="blue">future events</font> or our     <font color="blue">future financial performance</font></td>
    </tr>
    <tr>
      <td>In some cases, forward-looking statements can     be identified by <font color="blue">terminology</font> such as “may, “should,” “could,” “expect,”     “plan,”  “anticipate,”  “believe,”  “estimate,”  “predict,”  “intend,”     “potential” or “continue” or the negative of such terms or other comparable     <font color="blue">terminology</font></td>
    </tr>
    <tr>
      <td>These statements are <font color="blue">only <font color="blue"><font color="blue">expectation</font>s</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> our     investors that our <font color="blue"><font color="blue">expectation</font>s</font> and <font color="blue"><font color="blue">assumption</font>s will prove</font> to have been     correct</td>
    </tr>
    <tr>
      <td>We undertake <font color="blue">no intention</font> or <font color="blue">obligation</font> to update or revise any     forward-looking statements,       17     ______________________________________________________________________       <font color="blue">whether as</font> a result of <font color="blue">future events</font>, new information or otherwise</td>
    </tr>
    <tr>
      <td><font color="blue">Actual     </font>events  or  results  <font color="blue">may differ <font color="blue">materially</font> due</font> to a number of factors,     including those set forth in this section and elsewhere in this Form 10-K     These factors include, but are not limited to, the <font color="blue">risks set forth</font> below</td>
    </tr>
    <tr>
      <td>Risks Related to Our Development of DG031       The <font color="blue">Phase III </font><font color="blue">clinical trial</font> for DG031 will require the <font color="blue">recruitment</font> of     <font color="blue">patients <font color="blue">based on</font> ethnicity</font> and <font color="blue">haplotype status</font>; <font color="blue">recruitment</font> rates may be     lower than we expect <font color="blue">thus delaying</font> the trial and hurting our commercial     prospects</td>
    </tr>
    <tr>
      <td>In our <font color="blue">Phase III </font><font color="blue">clinical trial</font> for DG031, we will be testing the hypothesis     whether <font color="blue">African American </font>patients who (a) carry the HapK haplotype in LTA4H     and (b) have experienced a <font color="blue">hospitalization</font> and/or <font color="blue">admission</font> for procedures     and testing for unstable angina or myocardial <font color="blue">infarction</font> will experience     reduced rates of acute <font color="blue">cardiovascular</font> events when treated with DG031, as     compared to <font color="blue">placebo on top</font> of <font color="blue">concomitantly administered</font> standard of care</td>
    </tr>
    <tr>
      <td>In order to recruit a sufficient number of patients to obtain <font color="blue">statistically</font>     <font color="blue">significant</font>  evidence  for  the efficacy of DG031, we will require the     <font color="blue">participation</font> of a large number of <font color="blue">African American </font><font color="blue">patients willing</font> to be     tested for <font color="blue">haplotype status</font> and to <font color="blue">participate</font> in the <font color="blue">clinical trial</font> for at     least 12 months</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors outside</font> our <font color="blue"><font color="blue">control may</font> reduce</font> the <font color="blue">willingness</font>     of patients to be tested and <font color="blue">participate</font> in the <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>If we fail     to recruit a sufficient number of patients in a <font color="blue">timely manner</font> the trial may     be delayed or we may fail to show the efficacy of the drug</td>
    </tr>
    <tr>
      <td>This may delay     or prevent the <font color="blue">marketing approval</font> of DG031, <font color="blue">which could <font color="blue">adversely</font> impact</font> our     financial results and <font color="blue">commercial prospects</font></td>
    </tr>
    <tr>
      <td>We  have  only  indirect  evidence  from  <font color="blue">biomarkers studies about</font> the     <font color="blue"><font color="blue">effective</font>ness</font> of DG031 and this data may not be validated in the <font color="blue">Phase III </font>    <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">data collected during</font> the <font color="blue">Phase I and Phase II </font><font color="blue">clinical trial</font>s for     DG031, which is the basis for our <font color="blue">continuing <font color="blue">development</font></font> of this drug, does     not  provide  evidence  of whether DG031 will prove to be an <font color="blue">effective</font>     treatment  to  reduce  the  rate of acute <font color="blue">cardiovascular</font> events in the     <font color="blue">prospective treatment population</font></td>
    </tr>
    <tr>
      <td>In order to prove or disprove the validity     of our <font color="blue"><font color="blue">assumption</font> about</font> the efficacy of DG031, we will have to conduct the     <font color="blue">Phase III </font>trial, which will be of at least 36 months duration from the     <font color="blue">recruitment</font>  of  the  first patient, although the time <font color="blue">may vary due</font> to     <font color="blue">unforeseen circumstances</font></td>
    </tr>
    <tr>
      <td>Various <font color="blue">factors which</font> we do or do not <font color="blue">control may</font>     cause delays in the launch of the <font color="blue">clinical trial</font> or cause the trial to be     lengthier or <font color="blue">costlier than</font> anticipated</td>
    </tr>
    <tr>
      <td>Until data from the trial can be     collected  and analyzed we will not know whether DG031 is an <font color="blue">effective</font>     treatment and <font color="blue"><font color="blue">regulatory</font> review by</font> the FDA <font color="blue">will ultimately</font> determine whether     the drug gains <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>The outcome of this process is uncertain     and delays or failure to <font color="blue">gain market approval could <font color="blue">adversely</font> impact</font> our     financial results and <font color="blue">commercial prospects</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent protection</font> for DG031 <font color="blue">may provide marketing <font color="blue">exclusivity</font></font> for only a     limited term</td>
    </tr>
    <tr>
      <td>The patents we <font color="blue">licensed from</font> Bayer for DG031 expire in 2009 and 2012</td>
    </tr>
    <tr>
      <td><font color="blue">While     </font>we will seek to obtain one or more <font color="blue">use patents protecting</font> our <font color="blue">proprietary</font>     rights to <font color="blue">specific uses</font> of this compound for a <font color="blue">longer period</font>, we cannot be     certain  that we will obtain <font color="blue">such patents</font> or that they <font color="blue">will adequately</font>     <font color="blue">protect us</font></td>
    </tr>
    <tr>
      <td>In addition, although we may seek to extend the term of one of     the patents we <font color="blue">licensed from</font> Bayer and to obtain <font color="blue">marketing <font color="blue">exclusivity</font> under</font>     the Hatch-Waxman Act and equivalent foreign statutes, we cannot be certain     that we will be successful</td>
    </tr>
    <tr>
      <td><font color="blue">Expiration </font>of the patent(s) prior to <font color="blue">regulatory</font>     <font color="blue">approval may affect</font> our ability to gain the full benefit of <font color="blue">such possible</font>     <font color="blue">term extension</font>/marketing <font color="blue">exclusivity</font></td>
    </tr>
    <tr>
      <td>Further, even if <font color="blue">regulatory</font> approval     is received before <font color="blue">patent expiration</font>, the <font color="blue">US Patent and <font color="blue">Trademark Office </font>    </font>and/or FDA may not rule on our <font color="blue">application</font> for <font color="blue">term extension</font> in a timely     manner</td>
    </tr>
    <tr>
      <td>If we cannot obtain <font color="blue">new patents</font> or <font color="blue">fully extend</font> the term of patent     <font color="blue">protection under one</font> of the patents we <font color="blue">licensed from</font> Bayer, the amount of     revenues that we will be able to derive from an <font color="blue">approved product</font> <font color="blue">based on</font>     these patents may be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       Risks Related to Our Business       We may not <font color="blue">successfully</font> develop or <font color="blue">derive revenues from</font> any products</td>
    </tr>
    <tr>
      <td>We use our <font color="blue">technology</font> and <font color="blue">research <font color="blue">capabilities</font></font> to identify genes and gene     <font color="blue">variations</font>  that contribute to <font color="blue">certain diseases</font> and then develop small     molecule drugs that <font color="blue">target proteins</font> produced by these genes</td>
    </tr>
    <tr>
      <td>Although we     have identified genes that we believe are likely to cause <font color="blue">certain diseases</font>,     we may not be correct and may not be successful in identifying any other     similar  genes or in developing <font color="blue">drugs <font color="blue">based on</font></font> these <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>experts believe that some of the diseases we are targeting are caused by     <font color="blue">both genetic</font> and <font color="blue">environmental factors</font></td>
    </tr>
    <tr>
      <td>Even if we identify <font color="blue">specific genes</font>     that  are  <font color="blue">partly responsible</font> for causing diseases, any <font color="blue">therapeutic</font> or     <font color="blue"><font color="blue">diagnostic</font> products</font> we develop as a result of our genetic work may not     detect, prevent, treat or cure a <font color="blue">particular disease</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">pharmaceutical</font> or     <font color="blue"><font color="blue">diagnostic</font> products</font> that we or our <font color="blue">collaborators</font> are able to develop will     fail to produce <font color="blue">revenues unless</font> we:       ·       establish that they are safe and <font color="blue">effective</font>;       ·       <font color="blue">successfully</font> compete with other <font color="blue">technologies</font> and products;       ·        ensure that they do not infringe on the <font color="blue">proprietary</font> rights of     others;       ·       establish that they can be <font color="blue"><font color="blue">manufacture</font>d</font> in <font color="blue"><font color="blue">sufficient quantities</font> at</font>     <font color="blue"><font color="blue">reasonable cost</font>s</font>;       ·       obtain and maintain <font color="blue">regulatory</font> approvals for them; and       ·       can market them <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We may not be able to meet these <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>We expect that it will be     years,  if ever, before we will recognize <font color="blue">significant</font> revenue from the     <font color="blue">development</font> of <font color="blue">therapeutic</font> or <font color="blue"><font color="blue">diagnostic</font> products</font></td>
    </tr>
    <tr>
      <td>If we continue to incur operating <font color="blue">losses longer than</font> anticipated, or in     amounts  greater  than  anticipated,  we may be unable to continue our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We incurred a net loss of dlra62dtta8 million, 57dtta3 million and dlra35dtta1 million for     the years ended <font color="blue">December </font>31, 2005, 2004 and 2003, respectively, and had an     <font color="blue">accumulated deficit</font> of dlra450dtta2 million at <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We have never     generated a profit and we have not <font color="blue">generated revenues except</font> for payments     received in <font color="blue">connection with</font> our research and <font color="blue">development</font> <font color="blue">collaborations</font> with     Roche, Merck and others, from contract services, <font color="blue">Emerald BioSystems </font>products     and <font color="blue">instruments</font>, and <font color="blue">under grants</font></td>
    </tr>
    <tr>
      <td>Our research and <font color="blue">development</font> <font color="blue">expenditures</font>     and general and <font color="blue">administrative costs</font> have exceeded our revenue to date, and     we expect to spend <font color="blue">significant</font> <font color="blue">additional</font> amounts to <font color="blue">fund research</font> and     <font color="blue">development</font> in order to enhance our core <font color="blue">technologies</font> and undertake product     <font color="blue">development</font> (including drug <font color="blue">development</font> and related <font color="blue">clinical trial</font>s)</td>
    </tr>
    <tr>
      <td>We do     not expect to receive royalties or other <font color="blue">revenues from <font color="blue">commercial sale</font>s</font> of     products developed using our <font color="blue">technology</font> in the near term</td>
    </tr>
    <tr>
      <td>It may be several     years before <font color="blue"><font color="blue">product revenues</font> materialize</font>, if they do at all</td>
    </tr>
    <tr>
      <td>If the time required to     generate  <font color="blue">product revenues</font> and achieve <font color="blue">profitability</font> is longer than we     currently anticipate or the level of losses is <font color="blue">greater than</font> we currently     anticipate, we may not be able to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       If our <font color="blue"><font color="blue">assumption</font> about</font> the role of genes in disease is wrong, we may not be     able to develop <font color="blue">useful products</font></td>
    </tr>
    <tr>
      <td>The products we hope to develop <font color="blue">involve new</font> and <font color="blue">unproven approaches</font></td>
    </tr>
    <tr>
      <td><font color="blue">They     </font>are <font color="blue">based on</font> the <font color="blue">assumption</font> that information <font color="blue">about genes may help scientists</font>     to better understand <font color="blue">complex <font color="blue">disease process</font>es</font></td>
    </tr>
    <tr>
      <td><font color="blue">Scientists </font><font color="blue">generally</font> have a     limited understanding of the role of genes in diseases, and <font color="blue">few products</font>     <font color="blue">based on</font> gene <font color="blue">discoveries</font> have been developed</td>
    </tr>
    <tr>
      <td>Of the products that exist,     all are <font color="blue"><font color="blue">diagnostic</font> products</font></td>
    </tr>
    <tr>
      <td>To date, we know of no <font color="blue">therapeutic</font> products     <font color="blue">based on</font> disease-gene <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">assumption</font> about</font> the role of genes     in the <font color="blue">disease process</font> is wrong, our <font color="blue">gene <font color="blue">discovery</font> programs may</font> not result     in products</td>
    </tr>
    <tr>
      <td>In order to conduct <font color="blue">clinical trial</font>s and to market our drugs we will have to     develop methods to produce these <font color="blue">drugs using clinically approved methods</font> and     <font color="blue">at <font color="blue">commercially</font> viable rates</font>       In order to conduct <font color="blue">clinical trial</font>s we may need to <font color="blue"><font color="blue">contract with</font> third</font>     parties  in  order  to  obtain  <font color="blue">sufficient amounts</font> of our drugs</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue"><font color="blue">contractor</font>s</font>  need to implement the <font color="blue">necessary</font> <font color="blue">technology</font> and obtain the     <font color="blue"><font color="blue">necessary</font> ingredients</font> in order to produce the drugs to <font color="blue">exacting standards</font>     set by us and the <font color="blue">regulatory</font> bodies</td>
    </tr>
    <tr>
      <td>This is an uncertain and time consuming     process and any <font color="blue">disruption</font> in it may delay or harm our ability to continue     clinical  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">drugs which</font> have reached the last stage of     <font color="blue">clinical trial</font>s we will have to develop methods to scale up the production     of the drug <font color="blue">at <font color="blue">commercially</font> viable rates</font>, securing both a <font color="blue">contractor</font> or     <font color="blue">partner with</font> the ability to implement this process and obtain a secure and     <font color="blue">economical supply</font> of the <font color="blue"><font color="blue">necessary</font> ingredients</font></td>
    </tr>
    <tr>
      <td>If we are not able to scale     the process in a <font color="blue">timely manner</font> or do not have the ability to produce the     <font color="blue">drug economically</font>, we may not have the ability to enter the <font color="blue">market with</font> a     <font color="blue">viable product</font></td>
    </tr>
    <tr>
      <td>This would harm our financial and <font color="blue">commercial prospects</font></td>
    </tr>
    <tr>
      <td>Clinical trials required for our <font color="blue">product <font color="blue">candidates</font></font> or the products of our     customers and partners are expensive and time-consuming, their outcome is     uncertain and we may not achieve our projected <font color="blue">development</font> goals in the     timeframes we have announced and expect</td>
    </tr>
    <tr>
      <td>Before obtaining <font color="blue">regulatory</font> approvals for the <font color="blue">commercial sale</font> of any of our     products under <font color="blue">development</font>, we must demonstrate through pre-clinical studies     and <font color="blue">clinical trial</font>s that the product is safe and <font color="blue">effective</font> for use in each     <font color="blue">target <font color="blue">indication</font></font></td>
    </tr>
    <tr>
      <td>Pre-<font color="blue">clinical testing</font> and clinical <font color="blue">development</font> are long,     expensive and <font color="blue">uncertain processes</font></td>
    </tr>
    <tr>
      <td>It may take <font color="blue">several years</font> to complete     testing for a product and failure can occur at any stage of testing</td>
    </tr>
    <tr>
      <td>The     length of time <font color="blue">necessary</font> to complete <font color="blue">clinical trial</font>s varies <font color="blue">significant</font>ly     and may be <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>Factors that can cause delay or <font color="blue">termination</font>     of our <font color="blue">clinical trial</font>s include:       ·       <font color="blue">slower than</font> expected <font color="blue">patient enrollment due</font> to the nature of the     protocol, the proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility</font>     criteria for the study, <font color="blue">competition</font> with <font color="blue">clinical trial</font>s for other drug     <font color="blue">candidates</font> or other factors;       ·       lower than expected <font color="blue">retention rates</font> of patients in a <font color="blue">clinical trial</font>;       ·       <font color="blue">delayed approval</font> of <font color="blue">study protocol</font> and <font color="blue">pharmacogenomic components</font> of     studies by <font color="blue">regulatory</font> agencies in <font color="blue">different countries</font>, some of which are     still developing <font color="blue">policies <font color="blue">with respect</font></font> to  <font color="blue">pharmacogenomic testing</font>;       ·       <font color="blue">inadequately trained</font> or insufficient <font color="blue">personnel at</font> the study site to     assist in overseeing and monitoring  <font color="blue">clinical trial</font>s;       ·       delays in approvals or failure to obtain <font color="blue">approval from</font> the pertinent     <font color="blue">review boards</font> or <font color="blue">regulatory</font>  <font color="blue">authorities</font>;       ·       <font color="blue">longer treatment</font> time required to demonstrate <font color="blue"><font color="blue">effective</font>ness</font> or     determine the <font color="blue"><font color="blue">appropriate</font> product dose</font>;       ·       lack of <font color="blue">sufficient supply</font> of the <font color="blue">product candidate</font>;       20     ______________________________________________________________________       ·       <font color="blue">adverse medical events</font> or side effects in <font color="blue">treated patients</font>;       ·       lack of <font color="blue"><font color="blue">effective</font>ness</font> of the <font color="blue">product candidate</font> being tested; and       ·       <font color="blue">regulatory</font> changes</td>
    </tr>
    <tr>
      <td>Even if we obtain positive results from pre-clinical or <font color="blue">clinical trial</font>s for     a <font color="blue">particular product</font>, we may not achieve the <font color="blue">same success</font> in <font color="blue">future trials</font>     of  that  product</td>
    </tr>
    <tr>
      <td>In addition, some or all of the <font color="blue">clinical trial</font>s we     undertake may not <font color="blue">demonstrate sufficient safety</font> and efficacy to obtain the     requisite  <font color="blue">regulatory</font>  approvals,  <font color="blue">which could prevent</font> the creation of     <font color="blue">marketable products</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> costs will increase if we have     delays  in  testing or approvals, if we need to perform more or larger     <font color="blue">clinical trial</font>s than planned or if our trials are not successful</td>
    </tr>
    <tr>
      <td>Delays or <font color="blue">termination</font> of <font color="blue">clinical trial</font>s that we     conduct for our partners or <font color="blue">customers may</font> also harm our financial results as     payments under these contracts may be delayed, reduced or curtailed</td>
    </tr>
    <tr>
      <td>Co-<font color="blue">development</font> of <font color="blue">therapeutic</font> and <font color="blue"><font color="blue">diagnostic</font> products</font> may be required, and     delays  in  the  <font color="blue">development</font>  and approval of a <font color="blue"><font color="blue">commercially</font> available</font>     <font color="blue">diagnostic</font>  <font color="blue">may delay drug approval</font> or <font color="blue">impede market <font color="blue">acceptance</font></font> of the     <font color="blue">therapeutic</font> product</td>
    </tr>
    <tr>
      <td>The  use of some of our <font color="blue">therapeutic</font> <font color="blue">products may</font> be <font color="blue"><font color="blue">dependent</font> upon</font> the     selection of <font color="blue">patients using both clinical</font> and <font color="blue">genetic markers</font></td>
    </tr>
    <tr>
      <td>This may     require co-<font color="blue">development</font> and <font color="blue">clinical testing</font> of the <font color="blue">therapeutic</font> drug and a     related <font color="blue">diagnostic</font> product</td>
    </tr>
    <tr>
      <td>In the United States, <font color="blue">drug approval could</font> be     <font color="blue">delayed until</font> we <font color="blue">successfully</font> obtain FDA approval of the related <font color="blue">diagnostic</font>     product</td>
    </tr>
    <tr>
      <td>In addition, if the <font color="blue">diagnostic</font> test cannot be performed on a     <font color="blue"><font color="blue">commercially</font> viable basis</font>, it may <font color="blue">impede market <font color="blue">acceptance</font></font> of our approved     <font color="blue">therapeutic</font> products</td>
    </tr>
    <tr>
      <td>To <font color="blue">successfully</font> co-develop and market a drug and     <font color="blue">diagnostic</font>  we  may  also  need  to  establish and maintain successful     <font color="blue">partnerships</font>  <font color="blue">with <font color="blue">manufacturing</font></font> and <font color="blue">marketing partners</font> for <font color="blue">diagnostic</font>     products</td>
    </tr>
    <tr>
      <td>If <font color="blue">necessary</font> <font color="blue">partnerships</font> can not be established or maintained,     the <font color="blue">development</font> of our <font color="blue">therapeutic</font>s and/or <font color="blue">diagnostic</font>s may be delayed or may     fail</td>
    </tr>
    <tr>
      <td>If we are not able to obtain <font color="blue">sufficient <font color="blue"><font color="blue">additional</font> funding</font></font> to meet our     <font color="blue">capital requirements</font>, we may be forced to reduce or terminate our research     and product <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We  have  spent  substantial  amounts of cash to fund our research and     <font color="blue">development</font> <font color="blue">activities</font> and expect to continue to spend substantial amounts     for these <font color="blue"><font color="blue">activities</font> over</font> the next <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We expect to use cash to     collect, generate and <font color="blue">analyze genotypic</font> and <font color="blue">disease data from volunteers</font> in     our  disease-gene  research  programs;  to  <font color="blue">conduct drug <font color="blue">discovery</font></font> and     <font color="blue">development</font> <font color="blue">activities</font> (including <font color="blue">clinical trial</font>s); and to continue other     research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors will influence</font> our future     capital needs, including:       ·       the number, breadth and progress of our <font color="blue">discovery</font> and research     programs;       ·       our ability to <font color="blue">attract customers</font>;       ·       our ability to <font color="blue">commercialize</font> our <font color="blue">discoveries</font> and the resources we     devote to <font color="blue">commercialization</font>;       ·       the amount we spend to <font color="blue">enforce patent</font> claims and other <font color="blue">intellectual</font>     <font color="blue">property rights</font>; and       ·       the costs and timing of <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>We have relied on, and <font color="blue">may continue</font> to rely on, revenues generated by our     <font color="blue">corporate alliances</font> and fee-paying customers for <font color="blue">significant</font> funding of our     <font color="blue">research efforts</font></td>
    </tr>
    <tr>
      <td>Historically, a substantial portion of our revenue has     been <font color="blue">derived from</font> contracts with a limited number of <font color="blue">significant</font> customers</td>
    </tr>
    <tr>
      <td>Our <font color="blue">largest partner</font>, Roche, accounted for approximately 23prca, 30prca and 43prca of     our <font color="blue">consolidated revenue</font> in the years ended <font color="blue">December </font>31, 2005, 2004 and     2003, respectively</td>
    </tr>
    <tr>
      <td>Revenue under our <font color="blue">alliances with</font> <font color="blue">Merck       </font>21     ______________________________________________________________________       accounted for approximately 15prca, 22prca and 18prca of our <font color="blue">consolidated revenue</font> in     the years ended, <font color="blue">December </font>31, 2005, 2004 and 2003, respectively</td>
    </tr>
    <tr>
      <td>During the     year ended <font color="blue">December </font>31, 2005, divisions of the NIH represented 13prca of our     <font color="blue">consolidated revenue</font></td>
    </tr>
    <tr>
      <td>Work under the Merck <font color="blue">obesity agreement</font> and the <font color="blue">Roche     </font>2002 agreement has <font color="blue">been substantially</font> completed, and this may <font color="blue">significant</font>ly     lower our revenues and affect the <font color="blue">resources available</font> to support our drug     <font color="blue">discovery</font> programs, which will increase our need for <font color="blue"><font color="blue">additional</font> funding</font></td>
    </tr>
    <tr>
      <td>In addition, we may seek <font color="blue"><font color="blue">additional</font> funding</font> through public or <font color="blue">private equity</font>     offerings and <font color="blue">debt financings</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">additional</font>     financing when we need it or the <font color="blue">financing may</font> not be on terms favorable to     us or our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Stockholders’ <font color="blue">ownership will</font> be diluted if we raise     <font color="blue">additional</font> capital by issuing equity securities</td>
    </tr>
    <tr>
      <td>If  we  raise  <font color="blue">additional</font>  funds  <font color="blue">through <font color="blue">collaborations</font></font> and licensing     <font color="blue"><font color="blue">arrangement</font>s</font>, we may have to <font color="blue">relinquish rights</font> to some of our <font color="blue">technologies</font>     or <font color="blue">product <font color="blue">candidates</font></font>, or <font color="blue">grant licenses on unfavorable terms</font></td>
    </tr>
    <tr>
      <td>If adequate     funds  are not available, we would have to scale back or terminate our     <font color="blue">discovery</font> and <font color="blue">research programs</font> and product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of any products that we may develop <font color="blue">will depend upon</font>     the degree of market <font color="blue">acceptance</font> among physicians, patients, healthcare     payors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Any  products that we may develop may not <font color="blue">gain market <font color="blue">acceptance</font> among</font>     physicians, patients, healthcare payors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>If these     products do not achieve an <font color="blue">adequate level</font> of <font color="blue">acceptance</font>, we may not generate     material <font color="blue">product revenues</font> and we may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>The degree of     market  <font color="blue">acceptance</font>  of  any of our <font color="blue">product <font color="blue">candidates</font></font>, if approved for     <font color="blue">commercial sale</font>, will <font color="blue">depend on</font> a number of factors, including:       ·       <font color="blue">demonstration</font> of efficacy and safety in <font color="blue">clinical trial</font>s;       ·       the prevalence and severity of any side effects;       ·       potential or perceived <font color="blue"><font color="blue">advantages</font> over alternative treatments</font>;       ·       the timing of <font color="blue">market entry relative</font> to <font color="blue"><font color="blue">competitive</font> treatments</font>;       ·       the ability to offer our <font color="blue">product <font color="blue">candidates</font></font> for <font color="blue">sale at <font color="blue">competitive</font></font>     prices;       ·       <font color="blue">relative convenience</font> and ease of <font color="blue">administration</font>;       ·       the strength of marketing and <font color="blue">distribution support</font>;       ·       <font color="blue">sufficient <font color="blue">third party</font> coverage</font> or <font color="blue">reimbursement</font>; and       ·        the <font color="blue">product labeling</font> or <font color="blue">product insert</font> required by the FDA or     <font color="blue">regulatory</font> <font color="blue">authorities</font> in other countries</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font> develop a marketing and <font color="blue">sales force</font> or maintain     suitable <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">third parties</font> to market and sell our products,     our ability to deliver <font color="blue">products may</font> be impaired</td>
    </tr>
    <tr>
      <td>We currently have no experience in marketing or selling <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>In order to achieve <font color="blue">commercial success</font> for any <font color="blue">approved product</font>,     we must either develop a marketing and <font color="blue">sales force</font>, which will require     substantial  <font color="blue">additional</font>  funds and personnel, or, where <font color="blue">appropriate</font> or     permissible, enter into <font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">third parties</font> to market and sell     our products</td>
    </tr>
    <tr>
      <td>We might not be successful in developing marketing and sales     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>Further, we may not be able to <font color="blue">enter into marketing</font> and sales     <font color="blue"><font color="blue">agreements</font> with others on</font> acceptable terms, and any such <font color="blue"><font color="blue">arrangement</font>s</font>, if     entered into, may be terminated</td>
    </tr>
    <tr>
      <td>If we develop our own marketing and sales     <font color="blue">capability</font>,  it  <font color="blue">will compete with</font> other companies that currently have     experienced, well-funded and <font color="blue">larger marketing</font> and sales <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To the     extent that we enter into co-       22     ______________________________________________________________________       promotion or other sales and marketing <font color="blue"><font color="blue">arrangement</font>s</font> with other companies,     <font color="blue">revenues will <font color="blue">depend on</font></font> the efforts of others, which may not be successful</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">successfully</font> form and maintain suitable <font color="blue"><font color="blue">arrangement</font>s</font> with third     parties for the <font color="blue">manufacturing</font> of the products we may develop, our ability to     develop or deliver <font color="blue">products may</font> be impaired</td>
    </tr>
    <tr>
      <td>We have no experience in <font color="blue">manufacturing</font> products for <font color="blue">commercial purposes</font> and     do not have <font color="blue">manufacturing</font> <font color="blue">facilities</font> that can produce <font color="blue">sufficient quantities</font>     of  drugs for large scale <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>Accordingly, we must either     develop such <font color="blue">facilities</font>, which will require substantial <font color="blue">additional</font> funds, or     rely  on  contract  <font color="blue"><font color="blue">manufacture</font>rs</font>  for  the production of products for     <font color="blue">development</font> and <font color="blue">commercial purposes</font></td>
    </tr>
    <tr>
      <td>In order to conduct our currently     planned <font color="blue">Phase III </font><font color="blue">clinical trial</font> of DG031, we will have to <font color="blue">contract with</font>     <font color="blue">third parties</font> to <font color="blue">manufacture</font> a <font color="blue">sufficient supply</font> of the drug for the trial     and  to produce <font color="blue">tablets containing</font> DG031 in amounts sufficient for the     clinical  trial</td>
    </tr>
    <tr>
      <td>While we have <font color="blue">signed contracts with suppliers</font> for the     production of DG031 material and tablets for the planned launch of our     <font color="blue">Phase III </font><font color="blue">clinical trial</font>, we have not received the finished drug tablets,     and we may fail to secure <font color="blue">sufficient supply</font> of the drug in a <font color="blue">timely manner</font>     over the duration of the trial</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of our products for <font color="blue">clinical trial</font>s and <font color="blue">commercial purposes</font>     is subject to <font color="blue">Good Manufacturing Practices </font>(cGMP) <font color="blue">regulations</font> promulgated by     the FDA The <font color="blue">manufacture</font> of <font color="blue"><font color="blue">diagnostic</font> products</font> is subject to the FDA’s     quality  <font color="blue">system requirements</font> (QSR)</td>
    </tr>
    <tr>
      <td>In the event that we are unable to     develop satisfactory <font color="blue">manufacturing</font> <font color="blue">facilities</font> or obtain or retain third     party <font color="blue">manufacturing</font> for our products, we will not be able to <font color="blue">commercialize</font>     <font color="blue">such products</font> as planned</td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">enter into <font color="blue">agreements</font></font> for     the <font color="blue">manufacture</font> of <font color="blue">future products</font> with <font color="blue"><font color="blue">manufacture</font>rs</font> whose <font color="blue">facilities</font> and     <font color="blue">procedures <font color="blue">comply with</font> cGMP</font>, QSR and other <font color="blue">regulatory</font> requirements</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">current dependence upon others</font> for the <font color="blue">manufacture</font> of our <font color="blue">products may</font>     <font color="blue">adversely</font> affect our ability to develop and deliver <font color="blue"><font color="blue">such products</font> on</font> a     timely and <font color="blue"><font color="blue">competitive</font> basis</font> and, in the <font color="blue">longer term</font>, the <font color="blue">profit margin</font>, if     any, on the sale of <font color="blue">future products</font> and our ability to develop and deliver     <font color="blue"><font color="blue">such products</font> on</font> a timely and <font color="blue"><font color="blue">competitive</font> basis</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> the <font color="blue">Icelandic </font><font color="blue">population may limit</font> the <font color="blue">applicability</font> of our     <font color="blue">discoveries</font> to <font color="blue">certain <font color="blue">populations</font></font></td>
    </tr>
    <tr>
      <td>The  genetic make-up and prevalence of disease <font color="blue">generally</font> varies across     <font color="blue"><font color="blue">populations</font> around</font> the world</td>
    </tr>
    <tr>
      <td>Common complex diseases <font color="blue">generally</font> occur with a     similar frequency in <font color="blue">Iceland and other European </font><font color="blue">populations</font></td>
    </tr>
    <tr>
      <td>However, the     <font color="blue">populations</font> of other <font color="blue">nations may</font> be <font color="blue">genetically predisposed</font> to certain     diseases because of mutations not present in the <font color="blue">Icelandic </font>population</td>
    </tr>
    <tr>
      <td>As a     result,  we  and  our <font color="blue">partners may</font> be unable to develop <font color="blue">diagnostic</font> and     <font color="blue">therapeutic</font> products that are <font color="blue">effective</font> on all or a portion of people with     such  diseases</td>
    </tr>
    <tr>
      <td>For our business to succeed, we must be able to apply     <font color="blue">discoveries</font> that we make on the basis of the <font color="blue">Icelandic </font>population to other     markets</td>
    </tr>
    <tr>
      <td>If a substantial portion of <font color="blue"><font color="blue">participant</font>s</font> in our <font color="blue">genetics research studies</font>     withdraw their <font color="blue">informed consent</font>, our ongoing research may suffer</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> the <font color="blue">willingness</font> of <font color="blue">Icelandic </font>volunteers to <font color="blue">participate</font> in our     <font color="blue">genetics research studies</font></td>
    </tr>
    <tr>
      <td>All of the <font color="blue"><font color="blue">participant</font>s</font> in our <font color="blue">genetic studies</font>     have signed an <font color="blue">informed consent</font> form, <font color="blue">which gives deCODE <font color="blue">permission</font></font> to     <font color="blue">process data</font> and <font color="blue">blood samples</font> that the <font color="blue">participant</font> has donated for research     purposes</td>
    </tr>
    <tr>
      <td><font color="blue">Participants </font>may at any time revoke this <font color="blue"><font color="blue">permission</font> by withdrawing</font>     their consent</td>
    </tr>
    <tr>
      <td>If, for any reason, a substantial portion of <font color="blue"><font color="blue">participant</font>s</font> in     our studies were to withdraw their consent, we would not be able to continue     <font color="blue">population genetic research</font> in some or all of the diseases that we are     studying</td>
    </tr>
    <tr>
      <td>This <font color="blue">would diminish</font> our ability to <font color="blue">discover new drug targets</font> and     to  develop products <font color="blue">based on</font> these <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>If our ability to use     <font color="blue">population genetic data</font> is impaired, we may also not be able to fulfill some     <font color="blue">contractual</font> <font color="blue">obligation</font>s with our partners</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       If  we  fail to <font color="blue">protect confidential data adequately</font>, we <font color="blue">could incur</font> a     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Under  laws  and <font color="blue">regulations</font> in force in Iceland, including applicable     European laws, directives and <font color="blue">regulations</font>, all information <font color="blue">on individuals</font>     that is used in our <font color="blue">population research</font> is <font color="blue">anonymized under</font> the protocols     and <font color="blue">supervision</font> of the <font color="blue">Data Protection Authority of Iceland</font></td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">comply with</font> these laws and <font color="blue">regulations</font>, we could lose public support for     <font color="blue">participation</font> in our research and we could be liable to <font color="blue">legal action</font></td>
    </tr>
    <tr>
      <td>Any     failure to <font color="blue">comply fully with</font> all <font color="blue"><font color="blue">confidentiality</font> requirements could lead</font> to     <font color="blue">liability</font> for <font color="blue">damages incurred by individuals whose privacy</font> is violated, the     loss  of our customers and reputation and the loss of the goodwill and     <font color="blue">participation</font>   of  the  <font color="blue">Icelandic </font> population,  including  healthcare     <font color="blue">professionals</font></td>
    </tr>
    <tr>
      <td>These eventualities could <font color="blue">materially</font> <font color="blue">adversely</font> affect our     work in Iceland</td>
    </tr>
    <tr>
      <td>Some parts of our product <font color="blue">development</font> services create a risk of <font color="blue">liability</font>     from <font color="blue">clinical trial</font> <font color="blue"><font color="blue">participant</font>s</font> and the <font color="blue">parties with whom</font> we contract</td>
    </tr>
    <tr>
      <td>Through our wholly owned subsidiary Encode, we conduct <font color="blue">clinical trial</font>s of     products we are developing and <font color="blue">contract with</font> <font color="blue">drug companies</font> and clinical     <font color="blue">research <font color="blue">organizations</font></font> to perform a wide range of services to <font color="blue">assist them</font> in     <font color="blue">bringing new drugs</font> to market</td>
    </tr>
    <tr>
      <td>Our services include:       ·       supervising <font color="blue">clinical trial</font>s;       ·       data and <font color="blue">laboratory analysis</font>;       ·       patient <font color="blue">recruitment</font>; and       ·       acting <font color="blue">as investigators</font> in conducting <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>If, in the course of these trials or <font color="blue">activities</font>,       ·        we  do  not perform our services to <font color="blue">contractual</font> or <font color="blue">regulatory</font>     standards;       ·       we fail to obtain <font color="blue">permission</font> to <font color="blue">conduct trials from</font> the <font color="blue">appropriate</font>     <font color="blue">authorities</font> in Iceland;       ·       patients or <font color="blue">volunteers <font color="blue">suffer personal injury</font></font> caused by or death     <font color="blue">from adverse reactions</font> to the test drugs or otherwise;       ·        there  are  <font color="blue">deficiencies</font>  in  the <font color="blue">professional conduct</font> of the     <font color="blue">investigators with whom</font> we contract;       ·       our laboratories inaccurately report or fail to report lab results;     or       ·       our <font color="blue">informatics products violate rights</font> of <font color="blue">third parties</font>,       then we could be held liable for these <font color="blue">eventualities by</font> the <font color="blue">regulatory</font>     agencies or the <font color="blue">drug companies</font> and clinical <font color="blue">research <font color="blue">organizations</font></font> with whom     we  contract  or  by study <font color="blue"><font color="blue">participant</font>s</font></td>
    </tr>
    <tr>
      <td>We maintain product <font color="blue">liability</font>     insurance for claims arising from the use of products we are developing in     <font color="blue">clinical trial</font>s <font color="blue">conducted by</font> Encode and are covered by the product <font color="blue">liability</font>     insurance of the <font color="blue">drug companies</font> and clinical <font color="blue">research <font color="blue">organizations</font></font> for whom     we provide <font color="blue">clinical trial</font> services for claims arising from the use of their     products in such trials</td>
    </tr>
    <tr>
      <td>Such insurance may be inadequate and in any event     would not cover the risk of a <font color="blue">customer deciding</font> not to do business with us     as a result of <font color="blue">poor performance</font> or claims for a customer’s financial loss as     the result of our failure to perform our <font color="blue">contractual</font> <font color="blue">obligation</font>s properly</td>
    </tr>
    <tr>
      <td>Use of <font color="blue">therapeutic</font> or <font color="blue"><font color="blue">diagnostic</font> products</font> developed as a result of our     programs may result in product <font color="blue">liability</font> claims for which we have inadequate     insurance</td>
    </tr>
    <tr>
      <td>The users of any <font color="blue">therapeutic</font> or <font color="blue"><font color="blue">diagnostic</font> products</font> developed by us or our     <font color="blue">collaborators</font> as a result of our <font color="blue">discovery</font> or <font color="blue">research programs</font> (including     <font color="blue"><font color="blue">participant</font>s</font> in our <font color="blue">clinical trial</font>s) may bring product <font color="blue">liability</font> claims     against  us</td>
    </tr>
    <tr>
      <td>Except as described above <font color="blue">with respect</font> to <font color="blue">clinical trial</font>s     <font color="blue">conducted by</font> Encode, we currently do not carry <font color="blue">liability</font> insurance to cover     such claims (although we expect to obtain <font color="blue">such insurance</font>       24     ______________________________________________________________________       for  our  <font color="blue">Phase III </font>trial of DG031)</td>
    </tr>
    <tr>
      <td>We are not certain that we or our     <font color="blue">collaborators</font> will be able to obtain <font color="blue">such insurance</font> or, if obtained, that     <font color="blue">sufficient coverage</font> can be acquired at a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>If we cannot     protect against potential <font color="blue">liability</font> claims, we or our <font color="blue">collaborators</font> may find     it <font color="blue">difficult</font> or impossible to <font color="blue">commercialize</font> products</td>
    </tr>
    <tr>
      <td>Our fee-for-service work <font color="blue">bears certain risks</font> of <font color="blue">liability</font> to our customers</td>
    </tr>
    <tr>
      <td>Our subsidiaries, deCODE <font color="blue">chemistry</font>, Inc, <font color="blue">deCODE biostructures</font>, Inc, and     Emerald  Biosystems, Inc,  provide  services,  equipment and products     (including  software)  for  third  party  customers  who  pay  us on a     fee-for-service or <font color="blue">product basis</font></td>
    </tr>
    <tr>
      <td>In this function, we <font color="blue">often synthesize</font>     compounds, <font color="blue">manufacture</font> Active Pharmaceutical Ingredient (API) material and     <font color="blue">provide recommendations</font> for <font color="blue">research direction</font> for our customers</td>
    </tr>
    <tr>
      <td>We also     <font color="blue">provide contract research services</font> in X-ray <font color="blue">crystallographic structure</font>     de<font color="blue">termination</font> of protein-ligand complexes for customers, and <font color="blue">often recommend</font>     targets to customers <font color="blue">based on</font> these de<font color="blue">termination</font>s</td>
    </tr>
    <tr>
      <td>In addition, we sell     <font color="blue">instruments</font> and software to these customers</td>
    </tr>
    <tr>
      <td>We may be liable to our customers for damages if we perform <font color="blue">such services</font>     <font color="blue">negligently</font> or <font color="blue">with <font color="blue">willful misconduct</font></font>, or if we <font color="blue">provide customers with</font>     defective products, equipment or software</td>
    </tr>
    <tr>
      <td>We also may be held liable for     failure to <font color="blue">meet specifications</font> or failure to <font color="blue">comply with</font> other <font color="blue">contractual</font>     <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>While our <font color="blue">agreements</font> with customers limit our <font color="blue">liability</font> and     while we carry general commercial <font color="blue">liability</font> insurance, such <font color="blue">contractual</font>     <font color="blue">limitations may</font> not be <font color="blue">effective</font> in the event of our material breach of the     <font color="blue">agreements</font>, gross negligence, or <font color="blue">willful misconduct</font> and <font color="blue">such insurance</font> may     not be adequate</td>
    </tr>
    <tr>
      <td>We <font color="blue">also supply compounds</font> for <font color="blue">clinical trial</font>s <font color="blue">conducted by</font>     our customers</td>
    </tr>
    <tr>
      <td>In doing so, we <font color="blue">may provide materials</font> requiring <font color="blue">certification</font>     of  compliance  with cGMP <font color="blue">regulations</font> applicable to production of such     materials</td>
    </tr>
    <tr>
      <td>If we are found not to have <font color="blue">complied with such requirements</font>, we     <font color="blue">may incur <font color="blue">liabilities</font></font> related to <font color="blue">such failures</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">participant</font>s</font> in these     <font color="blue">trials <font color="blue">suffer personal injury</font></font> or death <font color="blue">from adverse reactions</font> to the test     drugs, we could be held liable to our customers or the <font color="blue"><font color="blue">participant</font>s</font></td>
    </tr>
    <tr>
      <td>We     maintain product <font color="blue">liability</font> insurance for claims arising from the use of     products we supply</td>
    </tr>
    <tr>
      <td>However, <font color="blue">such insurance</font> may be inadequate</td>
    </tr>
    <tr>
      <td>Failure to     perform to customer <font color="blue">expectation</font> also may limit future business from our     existing customers, or could result in the holdback of <font color="blue">certain payments due</font>     to us</td>
    </tr>
    <tr>
      <td>We <font color="blue">integrate software</font> and <font color="blue">products purchased</font> or <font color="blue">licensed from</font> third     <font color="blue">parties suppliers into certain</font> of our products, equipment and <font color="blue">software sold</font>     to our customers</td>
    </tr>
    <tr>
      <td>While we <font color="blue">evaluate such items</font> for defects and possible     <font color="blue">intellectual</font> property <font color="blue">infringement</font> issues, and attempt to obtain <font color="blue">contractual</font>     <font color="blue">protections</font>  from  suppliers, in the event any <font color="blue">such items purchased</font> or     <font color="blue">licensed from</font> suppliers are defective or violate <font color="blue">intellectual</font> property     rights of <font color="blue">third parties</font>, we may not be able to <font color="blue">fully recover</font> any of our     damages or our customers’ damages from suppliers of such items</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> where work for customers is conducted are subject to audits     by the FDA and by customers</td>
    </tr>
    <tr>
      <td>In the event we are found in non-compliance by     the FDA, there is a risk that <font color="blue">such <font color="blue">facility</font> may</font> be subject to corrective     <font color="blue">measures up</font> to and including the closure of the <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">closure would</font>     have  impact  on  our  ability to <font color="blue">meet customer</font> <font color="blue">obligation</font>s as well as     <font color="blue">obligation</font>s relating to our <font color="blue">internal programs</font></td>
    </tr>
    <tr>
      <td>Customer <font color="blue">audits may lead</font> to     disputes regarding <font color="blue">compliance with</font> <font color="blue">contractual</font> terms, which could lead to     potential disputes and/or <font color="blue">liabilities</font> as described above</td>
    </tr>
    <tr>
      <td>In  addition,  we  typically  have  the  <font color="blue">obligation</font>  to  maintain  the     <font color="blue">confidentiality</font> of <font color="blue">proprietary</font> information of our customers</td>
    </tr>
    <tr>
      <td>While we have     systems in place to ensure that such <font color="blue">confidentiality</font> is protected, we do     conduct work on our internal projects at the same <font color="blue">facilities</font> where we work     for our customers; therefore, there is an <font color="blue">increased risk</font> that <font color="blue">customers may</font>     claim that we have violated our <font color="blue">confidentiality</font> <font color="blue">obligation</font>s or used their     <font color="blue">proprietary</font> information in our <font color="blue">proprietary</font> projects</td>
    </tr>
    <tr>
      <td><font color="blue">Increased  </font>leverage  as  a result of our <font color="blue">convertible debt may harm</font> our     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>31, 2005, we had dlra158dtta6 million of <font color="blue"><font color="blue">outstanding debt</font> as reflected</font>     in our <font color="blue">balance sheet</font></td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">additional</font> <font color="blue">indebtedness</font> in the future and     our outstanding 3dtta5prca <font color="blue">Senior Convertible Notes       </font>25     ______________________________________________________________________       (the “Notes”) do not restrict our <font color="blue">future issuance</font> of <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>Our level     of  <font color="blue">indebtedness</font>  will  have  several  <font color="blue">important effects on</font> our future     <font color="blue">operations</font>, including, <font color="blue">without limitation</font>:       ·       a portion of our cash flow from <font color="blue">operations</font> will be dedicated to the     payment of any interest required <font color="blue">with respect</font> to outstanding <font color="blue">indebtedness</font>;       ·       increases in our outstanding <font color="blue">indebtedness</font> and <font color="blue">leverage will increase</font>     our  <font color="blue">vulnerability</font> to adverse changes in <font color="blue">general economic</font> and industry     <font color="blue">conditions</font>, as well as to <font color="blue"><font color="blue">competitive</font> pressure</font>; and       ·       <font color="blue">depending on</font> the levels of our <font color="blue">outstanding debt</font>, our ability to     obtain <font color="blue">additional</font> financing for working capital, capital <font color="blue">expenditures</font>,     <font color="blue">general corporate</font> and other <font color="blue">purposes may</font> be limited</td>
    </tr>
    <tr>
      <td>Our ability to make payments of principal and <font color="blue">interest on</font> our <font color="blue">indebtedness</font>     <font color="blue">depends upon</font> our future performance, which will be subject to the success of     our  <font color="blue">development</font> and <font color="blue">commercialization</font> of new <font color="blue">pharmaceutical</font> products,     <font color="blue">general economic</font> <font color="blue">conditions</font>, industry cycles and financial, business and     other  factors  <font color="blue">affecting</font> our <font color="blue">operations</font>, many of which are beyond our     control</td>
    </tr>
    <tr>
      <td>If we are not able to generate sufficient cash flow from <font color="blue">operations</font>     in the future to service our debt, we may be required, among other things:       ·       to seek <font color="blue">additional</font> financing in the debt or <font color="blue">equity markets</font>;       ·       to refinance or <font color="blue">restructure</font> all or a portion of our <font color="blue">indebtedness</font>,     including the Notes;       ·       to sell selected assets; or       ·       to reduce or delay <font color="blue">expenditures</font> on planned <font color="blue">activities</font>, including but     not  limited to <font color="blue">clinical trial</font>s, and <font color="blue">development</font> and <font color="blue">commercialization</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">measures might</font> not be sufficient to <font color="blue">enable us</font> to service our debt</td>
    </tr>
    <tr>
      <td>In     addition, any such financing, refinancing or sale of <font color="blue">assets might</font> not be     <font color="blue">available on economically</font> favorable terms</td>
    </tr>
    <tr>
      <td>We may be unable to hire and retain the <font color="blue">key personnel upon whom</font> our success     depends</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> the <font color="blue">principal members</font> of our <font color="blue">management</font> and <font color="blue">scientific staff</font>,     including Dr</td>
    </tr>
    <tr>
      <td>We have not entered into <font color="blue">agreements</font> with any of these people that     bind them to a <font color="blue">specific period</font> of <font color="blue">employment</font></td>
    </tr>
    <tr>
      <td>If any of these people leave,     our ability to conduct our <font color="blue">operations</font> may be <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>Our future     <font color="blue">success also will depend</font> in part on our ability to attract, hire and retain     <font color="blue">additional</font>  personnel</td>
    </tr>
    <tr>
      <td>There is <font color="blue">intense <font color="blue">competition</font></font> for <font color="blue">such qualified</font>     personnel and we cannot be certain that we will be able to continue to     attract  and  retain <font color="blue">such personnel</font></td>
    </tr>
    <tr>
      <td>Currency <font color="blue"><font color="blue"><font color="blue">fluctuation</font>s</font> may negatively affect</font> our <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We  primarily  expend or <font color="blue">generate cash</font> in US dollars, our functional     currency</td>
    </tr>
    <tr>
      <td>We <font color="blue">also publish</font> our <font color="blue">consolidated financial statements</font> in US     dollars</td>
    </tr>
    <tr>
      <td>Currency <font color="blue"><font color="blue">fluctuation</font>s</font> can affect our financial results because a     portion  of our <font color="blue">cash reserves</font>, our debt and our operating costs are in     <font color="blue">Icelandic </font>kronas</td>
    </tr>
    <tr>
      <td>A <font color="blue">fluctuation</font> of the <font color="blue">exchange rates</font> of the <font color="blue">Icelandic </font>krona     against the US dollar can thus <font color="blue">adversely</font> affect the “<font color="blue">buying power</font>” of our     <font color="blue">cash reserves</font> and revenues</td>
    </tr>
    <tr>
      <td>Most of our long-term <font color="blue">liabilities</font> are US     <font color="blue">dollar denominated</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">may enter into hedging transactions</font> if we     have  substantial <font color="blue">foreign currency exposure</font> in the future</td>
    </tr>
    <tr>
      <td>We may have     <font color="blue">increased exposure as</font> a result of <font color="blue"><font color="blue">investment</font>s</font> or <font color="blue">payments from collaborative</font>     partners</td>
    </tr>
    <tr>
      <td>Our <font color="blue">contracts may terminate upon</font> short notice</td>
    </tr>
    <tr>
      <td>This means that our <font color="blue">contracts could</font> be terminated for <font color="blue">numerous reasons</font>, any     of which may be beyond our <font color="blue">control such as</font> a       26     ______________________________________________________________________       reduction or <font color="blue">reallocation</font> of a customer’s research and <font color="blue">development</font> budget or     a change in a customer’s overall <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The loss of a large     contract or <font color="blue">multiple smaller contracts</font>, or a <font color="blue">significant</font> decrease in revenue     <font color="blue">derived from</font> a contract, could <font color="blue">significant</font>ly reduce our <font color="blue">profitability</font> and     require us to reallocate under-utilized physical and <font color="blue">professional resources</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Collaborative Relationships       If we are unable to form and maintain the <font color="blue">collaborative <font color="blue">relationships</font></font> that     our business strategy requires, our <font color="blue">programs will suffer</font> and we may not be     able to develop products</td>
    </tr>
    <tr>
      <td>Our strategy for developing products and <font color="blue">deriving revenues from them</font> is     <font color="blue">dependent</font>,  in  part,  upon  our  ability  to <font color="blue">enter into collaborative</font>     <font color="blue"><font color="blue">arrangement</font>s</font> with research <font color="blue">collaborators</font>, corporate partners and others</td>
    </tr>
    <tr>
      <td>We     <font color="blue">may rely on</font> these <font color="blue"><font color="blue">arrangement</font>s</font> both to provide funding <font color="blue">necessary</font> to our     product <font color="blue">development</font> and to obtain goods and services that we require for our     product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We do not have the <font color="blue">capacity</font> to conduct large scale     <font color="blue">Phase III </font><font color="blue">clinical trial</font>s and <font color="blue">will rely on</font> <font color="blue">partnerships</font> or <font color="blue">third party</font>     <font color="blue"><font color="blue">contractor</font>s</font> to conduct our <font color="blue">Phase III </font>trials, including our currently planned     <font color="blue">Phase III </font>trial of DG031</td>
    </tr>
    <tr>
      <td>We <font color="blue">will rely on</font> these <font color="blue">third parties</font> to <font color="blue">provide us</font>     with clinical material for the trial and various services <font color="blue">necessary</font> to     organize and conduct a multi-center, multinational study, as well as other     goods and services</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">entered into contracts</font> for all goods and     services  required  for the <font color="blue">Phase III </font>trial of DG031 at this time</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">arrangement</font> for this and other <font color="blue">Phase III </font><font color="blue">trials will</font> be subject to risks     described below, <font color="blue">with respect</font> to our <font color="blue">collaborative <font color="blue">relationships</font></font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">collaborations</font> are not successful or if we are not able to manage     multiple  <font color="blue">collaborations</font>  <font color="blue">successfully</font>, our <font color="blue">programs may suffer</font></td>
    </tr>
    <tr>
      <td>If we     increase the number of <font color="blue">collaborations</font>, it will become more <font color="blue">difficult</font> to     manage  the  various <font color="blue">collaborations</font> <font color="blue">successfully</font> and the potential for     conflicts  among  the <font color="blue">collaborators</font> as to rights to the <font color="blue">technology</font> and     <font color="blue">products generated under</font> work <font color="blue">conducted with us will increase</font></td>
    </tr>
    <tr>
      <td><font color="blue">Dependence </font>on <font color="blue">collaborative <font color="blue">relationships</font></font> may lead to delays in product     <font color="blue">development</font>, product defects and <font color="blue">disputes over rights</font> to <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We  have  formed, and may in the future form <font color="blue">additional</font>, collaborative     <font color="blue">relationships</font> (including <font color="blue">relationships</font> with clinical <font color="blue">research <font color="blue">organizations</font></font>     to conduct <font color="blue">clinical trial</font>s on our behalf) that will, in some cases, make us     <font color="blue">dependent</font> on <font color="blue">collaborators</font> for the pre-clinical studies and/or clinical     trials and for <font color="blue">regulatory</font> approval of any products that we are developing</td>
    </tr>
    <tr>
      <td>Failure of such <font color="blue">collaborators</font> to perform under these <font color="blue">agreements</font> properly in     a <font color="blue">timely manner</font>, or at all, may lead to delays in our product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue"><font color="blue">participant</font>s</font> in the trials <font color="blue">conducted by</font> our <font color="blue">collaborators</font>     <font color="blue">suffer personal injury</font> or death as a result of actions of the <font color="blue">collaborators</font>,     we could be held liable</td>
    </tr>
    <tr>
      <td>In some cases, our <font color="blue">agreements</font> with <font color="blue">collaborators</font>     typically allow them <font color="blue">significant</font> discretion in <font color="blue">electing whether</font> and how to     pursue such <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font> the amount and timing of resources     <font color="blue">collaborators</font> will devote to these programs or <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may stop supporting our products or <font color="blue">providing services</font> to     us if they develop or obtain rights to <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>Disputes may     arise in the <font color="blue">future over</font> the ownership of rights to any <font color="blue">technology</font> developed     with <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>These and other possible dis<font color="blue">agreements</font> between our     <font color="blue">collaborators</font> and <font color="blue">us could lead</font> to delays in the <font color="blue">collaborative research</font>,     <font color="blue">development</font> or <font color="blue">commercialization</font> of products</td>
    </tr>
    <tr>
      <td>Such dis<font color="blue">agreements</font> could also     result in <font color="blue">litigation</font> or require <font color="blue">arbitration</font> to resolve</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       Risks Related to Our Industry       Concerns  regarding  the  use of <font color="blue">genetic testing</font> results may limit the     <font color="blue">commercial viability</font> of any products we develop</td>
    </tr>
    <tr>
      <td>Other companies have developed <font color="blue"><font color="blue">genetic predisposition</font> tests</font> that have raised     <font color="blue">ethical concerns</font></td>
    </tr>
    <tr>
      <td>It is possible that employers or <font color="blue">others could discriminate</font>     against  people who have a <font color="blue">genetic predisposition</font> to <font color="blue">certain diseases</font></td>
    </tr>
    <tr>
      <td><font color="blue">Concern  </font>regarding  <font color="blue">possible discrimination may</font> result in <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">authorities</font> enacting restrictions or bans on the use of all, or certain     types of, <font color="blue">genetic testing</font></td>
    </tr>
    <tr>
      <td>Similarly, <font color="blue">such concerns may lead individuals</font> to     refuse to <font color="blue">use <font color="blue">genetic tests</font> even</font> if permissible</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors may limit</font> the     market for, and therefore the <font color="blue">commercial viability</font> of, products that our     <font color="blue">collaborators</font> and/or we may develop</td>
    </tr>
    <tr>
      <td>We  may  not  be able to compete <font color="blue">successfully</font> with other companies and     <font color="blue">government</font>  agencies  in the <font color="blue">development</font> and marketing of products and     services</td>
    </tr>
    <tr>
      <td>A number of companies are attempting to rapidly identify and <font color="blue">patent genes</font>     that cause diseases or an <font color="blue">increased susceptibility</font> to diseases</td>
    </tr>
    <tr>
      <td><font color="blue">Competition     </font>in this field and our other areas of business, including drug <font color="blue">discovery</font> and     <font color="blue">development</font>,  is intense and is expected to increase</td>
    </tr>
    <tr>
      <td>We have numerous     <font color="blue">competitors</font>,  including major <font color="blue">pharmaceutical</font> and <font color="blue">diagnostic</font> companies,     specialized  bio<font color="blue">technology</font>  firms,  <font color="blue">universities</font>  and  other  research     <font color="blue">institutions</font>,  and  other  <font color="blue">government</font>-sponsored entities and companies     <font color="blue">providing healthcare</font> information products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font>, including     Roche and Merck, <font color="blue">may also compete with us</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font>, either     alone or with <font color="blue">collaborators</font>, have <font color="blue">considerably</font> greater capital resources,     research and <font color="blue">development</font> staffs and <font color="blue">facilities</font>, and technical and other     <font color="blue">resources than</font> we do, <font color="blue">which may allow them</font> to <font color="blue">discover important genes</font> or     develop <font color="blue">drugs <font color="blue">based on</font></font> such <font color="blue">discoveries</font> before we do</td>
    </tr>
    <tr>
      <td>We believe that a     number of our <font color="blue">competitors</font> are developing <font color="blue">competing products</font> and services     that  may  be <font color="blue"><font color="blue">commercially</font> successful</font> and that are <font color="blue">further advanced</font> in     <font color="blue">development</font>  than our <font color="blue">potential products</font> and services</td>
    </tr>
    <tr>
      <td>To succeed, we,     <font color="blue">together with</font> our <font color="blue">collaborators</font>, must discover disease-predisposing genes,     <font color="blue">characterize</font> their functions, develop <font color="blue">genetic tests</font> or <font color="blue">therapeutic</font> products     and  related  information  services  <font color="blue">based on</font> such <font color="blue">discoveries</font>, obtain     <font color="blue">regulatory</font> and other approvals, and launch <font color="blue">such services</font> or products before     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Even if we or our <font color="blue">collaborators</font> are successful in developing     <font color="blue">effective</font>  products  or  services,  our  products and <font color="blue">services may</font> not     <font color="blue">successfully</font> compete with those of our <font color="blue">competitors</font>, including cases where     the <font color="blue">competing drugs use</font> the same mechanism of <font color="blue">action as</font> our products</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> may succeed in developing and <font color="blue">marketing products</font> and services     that are more <font color="blue">effective</font> than ours or that are marketed before ours</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors  </font>have established, and in the future may establish, patent     positions <font color="blue">with respect</font> to <font color="blue">gene sequences</font> related to our research projects</td>
    </tr>
    <tr>
      <td>Such  patent  positions  or  the <font color="blue">public availability</font> of <font color="blue">gene sequences</font>     comprising substantial portions of the <font color="blue">human genome could decrease</font> the     <font color="blue">potential value</font> of our research projects and make it more <font color="blue">difficult</font> for us     to compete</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also face <font color="blue">competition</font> from</font> other entities in gaining     access  to DNA <font color="blue">samples used</font> for research and <font color="blue">development</font> purposes</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> may also obtain <font color="blue">patent protection</font> or other <font color="blue">intellectual</font> property     rights that <font color="blue">could limit</font> our rights, or our customers’ ability, to use our     <font color="blue">technologies</font> or <font color="blue">databases</font>, or <font color="blue">commercialize</font> <font color="blue">therapeutic</font> or <font color="blue">diagnostic</font>s     products</td>
    </tr>
    <tr>
      <td>In  addition,  we  face, and <font color="blue">will continue</font> to face, intense     <font color="blue">competition</font>  from  other companies for collaborative <font color="blue"><font color="blue">arrangement</font>s</font> with     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies, for <font color="blue">establishing</font> <font color="blue">relationships</font>     with academic and research <font color="blue">institutions</font> and for licenses to <font color="blue">proprietary</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We expect <font color="blue">competition</font> to <font color="blue">intensify as technical advances</font> are made and become     more  widely  known</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">future <font color="blue">success will depend</font></font> in large part on     maintaining a <font color="blue"><font color="blue">competitive</font> position</font> in the <font color="blue">genomic field</font></td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">technological</font>     <font color="blue">development</font> may result in products or <font color="blue">technologies</font> becoming obsolete before     we recover the expenses we incur in developing them</td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue">successfully</font> will depend, in part, on our ability,     and that of our <font color="blue">collaborators</font>, to:       ·       develop <font color="blue">proprietary</font> products;       28     ______________________________________________________________________       ·       develop and maintain products that reach the market first, and are     <font color="blue">technological</font>ly superior to, and  more cost <font color="blue">effective</font> than, other products     on the market;       ·       obtain patent or other <font color="blue">proprietary</font> protection for our products and     <font color="blue">technologies</font>;       ·       attract and retain scientific and product <font color="blue">development</font> personnel;       ·       obtain required <font color="blue">regulatory</font> approvals; and       ·       <font color="blue">manufacture</font>, market and <font color="blue">sell products</font> that we develop</td>
    </tr>
    <tr>
      <td>Changes in outsourcing trends and economic <font color="blue">conditions</font> in the <font color="blue">pharmaceutical</font>     and bio<font color="blue">technology</font> <font color="blue">industries</font> could <font color="blue">adversely</font> affect our growth</td>
    </tr>
    <tr>
      <td>Economic factors and <font color="blue">industry trends</font> that affect our <font color="blue">primary customers</font>,     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies, also affect our business</td>
    </tr>
    <tr>
      <td>For     example, the practice of many companies in these <font color="blue">industries</font> has been to     outsource to <font color="blue">organizations</font> like us the conduct of genetic research, clinical     research, sales and marketing projects and <font color="blue">chemistry</font> and <font color="blue">structural biology</font>     research and <font color="blue">development</font> projects</td>
    </tr>
    <tr>
      <td>If these <font color="blue">industries</font> reduce their present     tendency to outsource those projects, our <font color="blue">operations</font>, <font color="blue">financial condition</font>     and <font color="blue">growth rate could</font> be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>These alliances     and <font color="blue"><font color="blue">arrangement</font>s</font> are both time consuming and complex and we face substantial     <font color="blue">competition</font> in <font color="blue">establishing</font> these <font color="blue">relationships</font></td>
    </tr>
    <tr>
      <td>In addition, our ability to     <font color="blue">generate new</font> business could be impaired by <font color="blue">general economic</font> downturns in our     customers’ <font color="blue">industries</font></td>
    </tr>
    <tr>
      <td>We have experienced increasing pressure on the part     of our customers to <font color="blue">reduce expenses</font>, including the use of our <font color="blue">services as</font> a     result of negative economic trends <font color="blue">generally</font> and in the <font color="blue">pharmaceutical</font>     industry</td>
    </tr>
    <tr>
      <td>If <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies discontinue or     decrease  their  usage of our services, for example, as a result of an     <font color="blue">economic slowdown</font> or increased <font color="blue">competition</font> from outsourcing companies in     India and China, our revenues and <font color="blue">earnings could</font> be lower than we expect,     and our <font color="blue">revenues may decrease</font> or not <font color="blue">grow at historical rates</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font> approvals for products resulting from our gene <font color="blue">discovery</font>     programs are not obtained, we will not be able to <font color="blue">derive revenues from</font> these     products</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">agencies must approve new drugs</font> and <font color="blue"><font color="blue">diagnostic</font> products</font> in the     countries in which they are to be marketed</td>
    </tr>
    <tr>
      <td>We cannot be certain that we can     obtain <font color="blue">regulatory</font> approval for any drugs or <font color="blue"><font color="blue">diagnostic</font> products</font> resulting     from our gene <font color="blue">discovery</font> programs</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> process can take many years     and require substantial resources</td>
    </tr>
    <tr>
      <td>Because some of the <font color="blue">products likely</font> to     result from our disease <font color="blue">research programs</font> involve the <font color="blue">application</font> of new     <font color="blue">technologies</font> and may be <font color="blue">based upon</font> a new <font color="blue">therapeutic</font> approach, various     <font color="blue">government</font> <font color="blue">regulatory</font> <font color="blue">authorities</font> may subject <font color="blue">such products</font> to substantial     <font color="blue">additional</font> review</td>
    </tr>
    <tr>
      <td>As a result, these <font color="blue">authorities</font> may grant <font color="blue">regulatory</font>     approvals  for these products more slowly than for products using more     <font color="blue">conventional</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">regulatory</font> approval may impose     <font color="blue">limitations on</font> the use of a drug or <font color="blue">diagnostic</font> product</td>
    </tr>
    <tr>
      <td>Even if a product is approved for marketing, it and its <font color="blue">manufacture</font>r must     <font color="blue">undergo continuing review</font></td>
    </tr>
    <tr>
      <td><font color="blue">Discovery </font>of <font color="blue">previously</font> unknown problems with a     product may require the performance of <font color="blue">additional</font> <font color="blue">clinical trial</font>s or the     change of the labeling of the product and may have <font color="blue">adverse effects on</font> our     business,  financial  condition  and  results of <font color="blue">operations</font>, including     withdrawal of the <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>Third party <font color="blue">reimbursement</font> and <font color="blue">health care reform policies may reduce market</font>     <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on the price and extent to which we will be     paid for our products by <font color="blue">government</font> and health <font color="blue">administration</font> <font color="blue">authorities</font>,     <font color="blue">private health insurers</font> and other <font color="blue">third party</font> payers</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>for     newly  approved  healthcare products is uncertain</td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payers</font>,     including Medicare in the United States, are <font color="blue"><font color="blue">increasingly</font> challenging</font> the     <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>They are <font color="blue">increasingly</font>     attempting to <font color="blue">contain healthcare costs by limiting both coverage</font> and the     level of <font color="blue">reimbursement</font> for new <font color="blue">therapeutic</font> products</td>
    </tr>
    <tr>
      <td>We cannot be certain     that any <font color="blue">third party</font> insurance coverage will be available to patients for     any products we discover or develop</td>
    </tr>
    <tr>
      <td>If <font color="blue">third party</font> payers do not       29     ______________________________________________________________________       <font color="blue">provide adequate coverage</font> and <font color="blue">reimbursement</font> levels for our products, the     market <font color="blue">acceptance</font> of these <font color="blue">products may</font> be <font color="blue">materially</font> reduced</td>
    </tr>
    <tr>
      <td>Numerous <font color="blue">government</font>s have <font color="blue">undertaken efforts</font> to <font color="blue">control growing healthcare</font>     costs through legislation, regulation and voluntary <font color="blue">agreements</font> with medical     <font color="blue">care providers</font> and <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>If <font color="blue">cost containment efforts</font>     limit the profits that can be <font color="blue">derived from</font> new drugs, our <font color="blue">customers may</font>     reduce  their research and <font color="blue">development</font> spending which could reduce the     business they outsource to us</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">corporate compliance</font> program cannot guarantee</font> that we are in compliance     with all <font color="blue">applicable federal</font> and state <font color="blue">regulations</font> in the United States,     Iceland, the European Union and elsewhere</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>, <font color="blue">manufacturing</font>, distribution, pricing, sales, marketing and     <font color="blue">reimbursement</font> of our products, <font color="blue">together with</font> our general <font color="blue">operations</font> are     subject to extensive federal and state <font color="blue">regulations</font> in the <font color="blue">United States </font>and     national or supra-national laws and <font color="blue">regulations</font> <font color="blue">in Europe </font>and other parts of     the world</td>
    </tr>
    <tr>
      <td>While we have developed and instituted a <font color="blue">corporate compliance</font>     program <font color="blue">based on</font> current best practices, we <font color="blue">cannot assure</font> you that we or our     employees are or will be in <font color="blue">compliance with</font> all <font color="blue">potentially applicable</font>     federal and state <font color="blue">regulations</font> and/or laws</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">comply with</font> any of     these <font color="blue">regulations</font> and/or laws, a range of <font color="blue">actions could</font> result, including,     but not limited to, the <font color="blue">termination</font> of <font color="blue">clinical trial</font>s, the failure to     approve a <font color="blue">product candidate</font>, restrictions on our products or <font color="blue">manufacturing</font>     processes, including withdrawal of our <font color="blue">products from</font> the market, <font color="blue">significant</font>     fines, exclusion from <font color="blue">government</font> healthcare programs or other sanctions or     <font color="blue">litigation</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> involve a risk of injury or <font color="blue">damage from <font color="blue">hazardous</font> materials</font>,     and if an <font color="blue">accident</font> were to occur, we could be subject to costly and damaging     <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>In the course of our work, we handle and produce <font color="blue">hazardous</font> materials and     <font color="blue">chemicals</font>  as  well  as  compounds  which  may  have  known or unknown     <font color="blue">characteristics</font>  such as toxicity and <font color="blue">reactivity</font> with other compounds</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have systems in place to <font color="blue">manage such compounds</font> and their     <font color="blue">characteristics</font>, the risk of <font color="blue">accident</font>al contamination or <font color="blue">injury from</font> these     <font color="blue">materials cannot</font> be <font color="blue">completely eliminated</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such contamination</font> or injury     could result in <font color="blue">negative effects</font> to our personnel or <font color="blue">facilities</font>, which could     lead  to <font color="blue">liabilities</font> as well as impacting our ability to <font color="blue">meet customer</font>     <font color="blue">obligation</font>s and conduct our <font color="blue">internal programs</font></td>
    </tr>
    <tr>
      <td>Risks Related to Our Intellectual Property       We may not be able to protect the <font color="blue">proprietary</font> rights that are critical to     our success</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to protect our products, our     <font color="blue">genealogy database</font> and <font color="blue">genotypic data</font> and any other <font color="blue">proprietary</font> <font color="blue">databases</font>     that we develop and our <font color="blue">proprietary</font> software and other <font color="blue">proprietary</font> methods     and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Despite our efforts to protect our <font color="blue">proprietary</font> rights,     <font color="blue">unauthorized parties may</font> be able to obtain and use information that we     regard as <font color="blue">proprietary</font></td>
    </tr>
    <tr>
      <td>While we require employees, business partners, academic <font color="blue">collaborators</font> and     <font color="blue">consultants</font>  to enter into <font color="blue">confidentiality</font> <font color="blue">agreements</font>, there can be no     assurance that <font color="blue">proprietary</font> information will not be disclosed, that others     will  not  in<font color="blue">dependent</font>ly  develop substantially equivalent <font color="blue">proprietary</font>     information and techniques, otherwise gain access to our trade secrets or     disclose such <font color="blue">technology</font>, or that we can <font color="blue">meaningfully protect</font> our trade     secrets</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> will depend in part on obtaining <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font>, bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     companies, including deCODE, are <font color="blue">generally</font> uncertain and <font color="blue">involve complex</font>     legal and factual <font color="blue">considerations</font> that are <font color="blue">constantly evolving</font></td>
    </tr>
    <tr>
      <td>We cannot be     sure that:       ·        any  of our pending patent <font color="blue">application</font>s will result in issued     patents;       ·        we  will develop <font color="blue">additional</font> <font color="blue">proprietary</font> <font color="blue">technologies</font> that are     patentable;       30     ______________________________________________________________________       ·       any <font color="blue">patents issued</font> to us or our <font color="blue">partners will provide</font> a basis for     <font color="blue">commercially</font>  viable  products,  will  <font color="blue">provide us</font> with any <font color="blue">competitive</font>     <font color="blue">advantages</font> or will not be challenged by <font color="blue">third parties</font>; or       ·       the patents of <font color="blue">others will</font> not have an adverse effect on our ability     to do business</td>
    </tr>
    <tr>
      <td>If  we  are  unable  to obtain <font color="blue">patent protection</font> for our <font color="blue">technology</font> or     <font color="blue">discoveries</font>,  the  value of our <font color="blue">proprietary</font> resources may be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>In addition, patent law relating to the scope of claims in the area of     genetics and gene <font color="blue">discovery</font> is <font color="blue">still evolving</font> and subject to <font color="blue">uncertainty</font>,     including in <font color="blue">areas important</font> to <font color="blue">us such as patenting</font> of <font color="blue">discoveries</font> for the     <font color="blue">development</font> of <font color="blue">therapeutic</font> methods, <font color="blue">diagnostic</font> methods and products that     <font color="blue">predict inherited susceptibility</font> to diseases and <font color="blue">diagnostic</font> methods and     products that <font color="blue">predict drug response</font> and <font color="blue">disease progression</font></td>
    </tr>
    <tr>
      <td>Accordingly,     the degree of future protection for our <font color="blue">proprietary</font> rights is uncertain and,     we cannot predict the breadth of claims allowed in any <font color="blue">patents issued</font> to us     or others</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also incur</font> substantial costs in <font color="blue">litigation</font> if we are     required to <font color="blue">defend ourselves</font> in patent suits brought by <font color="blue">third parties</font> or if     we  initiate  such  suits to enforce our own <font color="blue">patents against potential</font>     <font color="blue">infringers</font></td>
    </tr>
    <tr>
      <td>Others  may  have  filed  and  in the future are likely to <font color="blue">file patent</font>     <font color="blue">application</font>s covering products or <font color="blue">technology</font> that are similar or identical     to our products and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>The fact that patent <font color="blue">application</font>s of others     may not <font color="blue">publish until</font> they <font color="blue">issue as patents</font> in the US, or are not published     until 18 months after filing <font color="blue">in the US </font>and other <font color="blue">jurisdictions may</font> have     adverse effect on our own <font color="blue">patent filings</font> and business, <font color="blue">particularly</font> if they     claim subject matter similar to that of our <font color="blue">clinical programs</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">others may</font> develop <font color="blue">competitive</font> products outside the protection that may be     <font color="blue">afforded by</font> the claims of our patents</td>
    </tr>
    <tr>
      <td>We cannot be certain that our patent     <font color="blue">application</font>s will have <font color="blue">priority over</font> any patent <font color="blue">application</font>s of others</td>
    </tr>
    <tr>
      <td>The     mere  issuance  of  a  patent  does  not guarantee that it is valid or     enforceable; thus even if we are holding or are <font color="blue">granted patents</font>, we cannot     be sure that they would be valid and enforceable against <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">legal action</font>     <font color="blue">against us</font> or our partners claiming damages and seeking to <font color="blue">enjoin commercial</font>     <font color="blue">activities</font>  relating  to the <font color="blue">affected products</font> and processes could, in     addition to <font color="blue">subjecting us</font> to potential <font color="blue">liability</font> for damages, require us or     our partners to obtain a license in order to continue to <font color="blue">manufacture</font> or     market the <font color="blue">affected products</font> and processes</td>
    </tr>
    <tr>
      <td>There can be no assurance that     we or our <font color="blue">partners would prevail</font> in any action or that any license required     under any <font color="blue">patent would</font> be made available on <font color="blue">commercially</font> acceptable terms,     if at all</td>
    </tr>
    <tr>
      <td>If licenses are not available, we or our <font color="blue">partners may</font> be required     to <font color="blue">cease marketing</font> our products or practicing our methods</td>
    </tr>
    <tr>
      <td>If expressed sequence tags, SNPs, or other sequence information become     <font color="blue">publicly available</font> before we apply for <font color="blue">patent protection</font> on a <font color="blue">corresponding</font>     full-length or <font color="blue">partial gene</font>, our ability to obtain <font color="blue">patent protection</font> for     those genes or <font color="blue">gene sequences</font> could be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>In addition,     other parties are attempting to rapidly identify and <font color="blue">characterize</font> genes     through  the use of SNP genotyping, gene expression analysis and other     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If any patents are issued to other <font color="blue">parties on</font> these partial or     full-length genes or <font color="blue">gene products</font> or uses for such genes or <font color="blue">gene products</font>,     the <font color="blue">risk increases</font> that the sale of our or our <font color="blue">collaborators</font>’ potential     products or <font color="blue">processes may give rise</font> to claims of <font color="blue">patent <font color="blue">infringement</font></font></td>
    </tr>
    <tr>
      <td>The     amount  of  <font color="blue">supportive data</font> required for issuance of patents for human     <font color="blue">therapeutic</font>s is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>If more data than we have available is     required,  our ability to obtain <font color="blue">patent protection</font> could be delayed or     otherwise <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Even with <font color="blue">supportive data</font>, the ability to     obtain patents is uncertain in view of evolving examination <font color="blue">guidelines</font>, such     as the utility and written description <font color="blue">guidelines</font> that the US Patent and     <font color="blue">Trademark Office </font>has adopted</td>
    </tr>
    <tr>
      <td>Our patent <font color="blue">application</font>s covering DG041, DG051 and DG061 have not <font color="blue">issued yet</font>     as patents</td>
    </tr>
    <tr>
      <td>The <font color="blue">most important compounds</font> that we have currently in pre-clinical and     clinical <font color="blue">development</font> and we have <font color="blue">discovered ourselves</font> are DG041, DG051 and     DG061</td>
    </tr>
    <tr>
      <td>We have <font color="blue">filed composition</font> of matter-type patent <font color="blue">application</font>s covering     the compounds <font color="blue">in the US </font>However, these patent <font color="blue">application</font>s are in the early     stages of <font color="blue">patent prosecution</font> before the <font color="blue">United States </font>Patent and Trademark     Office (USPTO) and we have       31     ______________________________________________________________________       <font color="blue">no certainty</font> or <font color="blue">indication</font> from <font color="blue">the USPTO </font>that these patent <font color="blue">application</font>s     will <font color="blue">issue as patents</font></td>
    </tr>
    <tr>
      <td><font color="blue">The USPTO </font>is <font color="blue">currently facing</font> considerable backlog     for examining pending patent <font color="blue">application</font>s so considerable time may elapse     before we will have more <font color="blue">certainty as</font> to the <font color="blue">patentability</font> of the compounds</td>
    </tr>
    <tr>
      <td>Should <font color="blue">the USPTO </font><font color="blue">ultimately reject</font> our patent <font color="blue">application</font>s covering DG041,     DG051  or DG061, or should others have filed or obtained issued patent     covering  the  same, the value and potential of these programs for our     business would be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Any <font color="blue">patent protection</font> we obtain for our <font color="blue">products may</font> not <font color="blue">prevent marketing</font>     of similar <font color="blue">competing products</font></td>
    </tr>
    <tr>
      <td>Patents on our <font color="blue">products may</font> not prevent our <font color="blue">competitors</font> from designing     around and developing similar compounds or <font color="blue">compounds with</font> similar modes of     action that may compete <font color="blue">successfully</font> with our products</td>
    </tr>
    <tr>
      <td>Such <font color="blue">third party</font>     <font color="blue">compounds may prove</font> to be superior to our products or <font color="blue">gain wider market</font>     <font color="blue">acceptance</font>  and thus <font color="blue">adversely</font> affect any <font color="blue">revenue stream</font> that we could     otherwise expect from sales of our products</td>
    </tr>
    <tr>
      <td>Any patents we obtain may be <font color="blue">challenged by producers</font> of <font color="blue">generic drugs</font></td>
    </tr>
    <tr>
      <td>Patents covering innovative drugs, which are <font color="blue">also commonly referred</font> to as     “<font color="blue">branded drugs</font>” or “pioneer drugs,” face increased scrutiny and <font color="blue">challenges</font>     in the courts from <font color="blue"><font color="blue">manufacture</font>rs</font> of <font color="blue">generic drugs</font> who may receive benefits     such as limited marketing co-<font color="blue">exclusivity</font> if the challenge is successful</td>
    </tr>
    <tr>
      <td>Such patent <font color="blue">challenges</font> typically occur when the generic <font color="blue">manufacture</font>r files     an <font color="blue">Abbreviated New Drug Application </font>with the FDA and asserts that the patent     or patents covering the branded drug are invalid or unenforceable, forcing     the  owner  or  licensee  of  the branded drug to file suit for patent     <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>If any patents we obtain covering our <font color="blue">pharmaceutical</font> products     are subject to such successful patent <font color="blue">challenges</font>, our marketing <font color="blue">exclusivity</font>     may be eliminated or reduced in time, which would thus <font color="blue">adversely</font> affect any     <font color="blue">revenue stream</font> that we could otherwise expect from sales of our products</td>
    </tr>
    <tr>
      <td>Risks Related to Investing in Our Stock       Future sales of <font color="blue"><font color="blue">common stock</font> may dilute</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may <font color="blue">sell <font color="blue">common stock</font></font></font> in the future in one or more <font color="blue">transactions at prices</font>     and in a manner we determine from time to time</td>
    </tr>
    <tr>
      <td>If we <font color="blue">sell <font color="blue">common stock</font></font> in     more than one transaction, existing <font color="blue">stockholders</font> who <font color="blue">previously</font> purchased     stock may be <font color="blue">materially</font> diluted by subsequent sales of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> is volatile and the <font color="blue">market value</font> of your     <font color="blue"><font color="blue">investment</font> may decrease</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>s for <font color="blue">common stock</font> of bio<font color="blue">technology</font> and <font color="blue">pharmaceutical</font>     companies, including ours, have <font color="blue">historically been highly volatile</font>, and the     market  has from time to time experienced <font color="blue">significant</font> price and volume     <font color="blue"><font color="blue">fluctuation</font>s</font> that are unrelated to the <font color="blue">actual performance</font> of particular     companies</td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">various risks described elsewhere</font> in this     Form 10-K, the <font color="blue">following factors could</font> have an adverse effect on the market     price of our <font color="blue">common stock</font>:       ·       <font color="blue"><font color="blue">fluctuation</font>s</font> in our operating results;       ·        <font color="blue">announcement</font>  of <font color="blue">technological</font> innovations or new <font color="blue">therapeutic</font>     <font color="blue">products by us</font> or others;       ·       <font color="blue">clinical trial</font> results;       ·       <font color="blue">development</font>s concerning <font color="blue">agreements</font> with <font color="blue">collaborators</font>;       ·       actual or threatened <font color="blue">litigation</font>;       ·       <font color="blue"><font color="blue">government</font>al</font> regulation and <font color="blue">regulatory</font> actions;       ·       changes in <font color="blue">patent laws</font>;       ·       <font color="blue">development</font>s concerning patent or other <font color="blue">proprietary</font> rights;       ·       public concern as to the safety of drugs developed by us or others;       32     ______________________________________________________________________       ·       <font color="blue">future sales</font> of substantial amounts of <font color="blue">common stock</font> by existing     <font color="blue">stockholders</font>; and       ·       general market <font color="blue">conditions</font> and economic and other <font color="blue">external factors</font>,     including disasters, wars and other crises</td>
    </tr>
    <tr>
      <td>We <font color="blue">may issue <font color="blue">preferred stock</font> with rights</font> that <font color="blue">could affect</font> your rights and     prevent a takeover of the business</td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> has the authority, without further approval of our     <font color="blue">stockholders</font>,  to  fix  the rights and <font color="blue">preferences</font>, and to issue up to     6cmam716cmam666 shares of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">Delaware </font><font color="blue">corporate law</font>     imposes <font color="blue">limitations on</font> certain business <font color="blue">combinations</font></td>
    </tr>
    <tr>
      <td>These provisions     could, under certain circumstances, delay or prevent a change in control of     deCODE and, accordingly, could <font color="blue">adversely</font> affect the price of our common     stock</td>
    </tr>
    <tr>
      <td>We  currently  do  not intend to <font color="blue">pay dividends on</font> our <font color="blue">common stock</font> and     <font color="blue">consequently</font>, your <font color="blue">only opportunity</font> to achieve a return on your <font color="blue">investment</font>     is if the price of our <font color="blue">common stock</font> appreciates</td>
    </tr>
    <tr>
      <td>We currently do not plan to <font color="blue">pay dividends on</font> shares of our <font color="blue">common stock</font> in     the near future</td>
    </tr>
    <tr>
      <td>Consequently, your <font color="blue">only opportunity</font> to achieve a return on     your <font color="blue">investment</font> in our <font color="blue">company will</font> be if the <font color="blue">market price</font> of our common     stock appreciates</td>
    </tr>
  </tbody>
</table>